Published in final edited form as:

ACS Chem Biol. 2010 May 21; 5(5): 461–476. doi:10.1021/cb100008p.

Targeted delivery of antigen processing inhibitors to antigen presenting cells via mannose receptors

Eun-Ang Raiber¹, Calogero Tulone², Yanjing Zhang², Luisa Martinez-Pomares³, Emily Steed¹, Anna M. Sponaas⁴, Jean Langhorne⁴, Mahdad Noursadeghi², Benjamin M. Chain^{#2}, and Alethea B. Tabor^{#1}

¹Dept of Chemistry, UCL, London, UK

²Division of Infection and Immunity, UCL, London, UK

³School of Molecular Medical Sciences, University of Nottingham, UK

⁴Division of Parasitology, National Institute for Medical Research, London, UK

[#] These authors contributed equally to this work.

Abstract

Improved chemical inhibitors are required to dissect the role of specific antigen processing enzymes and to complement genetic models. In this study we explore the *in vitro* and *in vivo* properties of a novel class of targeted inhibitor of aspartic proteinases, in which pepstatin is coupled to mannosylated albumin (MPC6), creating an inhibitor with improved solubility and the potential for selective cell tropism. Using these compounds, we have demonstrated that MPC6 is taken up via mannose receptor facilitated endocytosis, leading to a slow but continuous accumulation of inhibitor within large endocytic vesicles within dendritic cells, and a parallel inhibition of intracellular aspartic proteinase activity. Inhibition of intracellular proteinase activity is associated with reduction in antigen processing activity, but this is epitope specific, preferentially inhibiting processing of T cell epitopes buried within compact proteinase-resistant protein domains. Unexpectedly, we have also demonstrated, using quenched fluorescent substrates, that little or no cleavage of the disulfide linker takes place within dendritic cells, but this does not appear to affect the activity of MPC6 as an inhibitor of cathepsins D and E *in vitro* and *in vivo*. Finally, we have shown that MPC6 selectively targets dendritic cells and macrophages in spleen *in vivo*. Access to non-lymphoid tissues is very limited in the steady state, but is strongly enhanced at local sites of inflammation. The strategy adopted for MPC6 synthesis may therefore represent a more general way to deliver chemical inhibitors to cells of the innate immune system, especially at sites of inflammation.

Antigen presenting cells (including dendritic cells (DC) and macrophages) are equipped with an array of membrane and cytoplasmic receptors known as Pattern Recognition Receptors (PRR), with which they bind to microbial components (Pathogen Associated Molecular Patterns, PAMPs). Once internalised, any PAMP-associated proteins are subject to regulated proteolysis (the exogenous antigen processing pathway), producing peptides which bind to Class II Major Histocompatibility Complex (MHC) receptors, and hence stimulate T cell adaptive immunity¹. The interaction between antigen presenting cell and T cell is widely recognised as being one of the key steps regulating both the magnitude and the

type of immune response. The experimental manipulation of antigen presenting cells, either to enhance therapeutic and protective responses or to inhibit pathogenic responses, is therefore an important goal of applied immunology. Efficient delivery of such immunomodulators is one limiting factor in achieving this goal.

A number of studies have used antibodies to deliver antigens to antigen presenting cells in vitro or in vivo ². This has achieved some significant successes. However, a wealth of experience from the field of tumour biology has shown that delivery of drugs via antibody conjugates poses formidable technical problems. An alternative approach is to target DC using ligands of lectins such as mannose receptors, themselves a family of PRRs ^{3,4}. We have explored this targeting strategy in the context of using the selective inhibitor pepstatin **1** to identify the role of aspartic proteinases cathepsins D and E in the proteolysis of antigen ^{5,6}. Pepstatin itself is a very potent inhibitor ($IC_{50} < 1 \text{ nM}$ for both cathepsins D and E). However pepstatin is almost completely insoluble in aqueous solution, and its peptidic nature gives very poor cell penetration. As a result, it is typically used at 10-100 μM in vitro, concentrations at which it rapidly forms crystalline deposits in tissue culture. In addition to improving its solubility, selective cellular targeting of pepstatin is desirable, since cathepsin D deficiency is known to result in profound neurotoxicity ⁷.

Our previous work addressed these issues by designing a mannose-pepstatin conjugate, MPC6 **2** (Fig 1a) in which pepstatin is coupled to neomannosylated bovine serum albumin (BSA) via a disulfide linker. These initial studies confirmed that this strategy resulted in an inhibitor with increased solubility, which could inhibit processing of a model antigen ovalbumin (OVA) by bone marrow derived GM-CSF DC. However, only one T cell response was examined, and no information was available on uptake, intracellular distribution and cell targeting of MPC6. In this study we synthesised a number of fluorescently labelled derivatives of MPC6, in order to follow uptake, endocytosis and processing of MPC6 by DC.

RESULTS AND DISCUSSION

Synthesis of fluorophore-labelled analogues of MPC6

Fluorophore-labelled analogues of MPC6 were prepared using a modification of the approach that we have previously reported.⁵ Starting from the key intermediate **3**, the Boc protecting group was removed and the resulting free amine coupled to the activated NHS ester of pepstatin⁵ to give **4** (Fig 1b). Removal of the Fmoc group, followed by conversion to the iodoacetamide and coupling to neomannosylated BSA **5** gave MPC6-32 **6**. For the second mono-labelled analogue, selective removal of the Fmoc group from **3** and coupling to pepstatin-NHS gave **7**, which was again deprotected, converted to the iodoacetamide and coupled to neomannosylated BSA to give MPC6-40 **8**. Two probes were prepared with fluorophores in different positions relative to the disulfide bond, in order to investigate whether disulfide bond cleavage took place after uptake of MPC6, and the site and timing of such cleavage⁸. In MPC6-32 **6**, the tetramethyl rhodamine (TMR) label is placed on the mannose-BSA conjugate side of the disulfide bond. If the disulfide linker is cleaved, for example by intracellular reduction, the label should remain with the mannose-BSA conjugate. Conversely, in MPC6-40 **8**, the TMR label is placed on the side of the pepstatin,

and should therefore remain with the inhibitor after cleavage of the disulfide linker. Measurements of TMR:BSA ratios by light absorption spectroscopy gave yields of around 1 TMR for every 2-3 BSA molecules. However, no remaining free thiol group could be detected by the Ellman test on either inhibitor. These results are consistent with many previous studies showing that only 30-50% of serum albumin molecules contain a reactive free thiol group, with the Cys residue in the remainder in the form of mixed disulfides or oxidised to sulfenic and sulfonic acids, and hence unreactive to iodoacetamides ⁹. Additionally, the BSA free sulfhydryl is buried within a hydrophobic site, and is thus less accessible for reaction with iodoacetamides ¹⁰, also rendering the Ellman's test less reliable for measuring successful conjugation ¹¹.

Uptake and retention of MPC6 analogues within DC

The binding/uptake of MPC6-32 and MPC6-40 by DC were first investigated by flow cytometry. Mouse DC can be isolated and/or differentiated in vitro following a number of different protocols. In vitro culture of bone marrow precursors in GM-CSF gives rise to a population of cells which is 60-90% CD11c positive, with the remaining cells mostly immature DC precursors. MPC6-32 (Fig 2a) and MPC6-40 (Supplementary Information Fig 1) are both taken up selectively by the CD11c positive fraction of cells. Uptake by DC is both dose and time dependent (Fig 2b). The rate of uptake is slow, and continues to increase over 18 hours, the longest time period tested (Fig 2c). The rate does not saturate over the range of concentrations tested at early time points, suggesting a low affinity interaction facilitates uptake. However, concentration-dependent saturation is observed at longer time points (Fig 2c), suggesting that there is a maximum amount of inhibitor which can be taken up by each cell.

An alternative protocol for DC differentiation is to expand precursor cells in the growth factor Flt3L. This protocol produces a population which is almost entirely CD11c positive, but can be subdivided into two subpopulations, expressing high and low levels of CD11b¹². Although both populations were able to take up MPC6-32 (and MPC6-40, Supplementary Information Fig 2), the CD11b high population was more efficient (Fig 2d), consistent with the fact that this population is believed to play the major role in uptake and processing of exogenous antigens via the class II MHC pathway ¹³.

Remarkably, efflux of MPC-32 (Fig 2e) and MPC-40 (Supplementary Information Fig 3) is extremely slow, with a half life of over three hours. Thus MPC6 appears to be continuously accumulated by the cell, with very little concomitant loss once uptake has occurred. Uptake of MPC6-32 and MPC6-40 is also strictly temperature dependent, and is blocked almost completely at 4°C (Fig 2f), consistent with a process requiring active internalisation, rather than simple equilibrium binding to a receptor. Uptake was also partly blocked in the presence of chloroquine (Fig 2g), which inhibits intracellular acidification, consistent with a model in which MPC6 is taken into the cell via a receptor, and then falls off the receptor at the acidic pH of the endosome.

As predicted, uptake involved a saturable interaction with the mannose residues of MPC6, since uptake could be competitively inhibited by excess mannosylated -BSA, but not by BSA alone (Fig 2g). 50% inhibition of uptake required concentrations above 7.5 μ M

competitor, consistent with the relatively low affinity interaction between mannose receptors and their ligands¹⁴. DC express a number of receptors of the lectin family, several of which can potentially bind mannose residues. Two lectin receptors which have received particular attention are DEC 205¹⁵, and the classical mannose receptor¹⁶. Both are expressed on bone marrow derived mouse DC. As shown in Fig 3b), even very high concentrations of a monoclonal antibody to DEC205, NLDC145, which have been shown to block uptake of apoptotic cells via this receptor¹⁷, were unable to block uptake of MPC-32. This result is consistent with the structure of DEC205, which, although belonging to the lectin family, lacks the classical mannose binding domains¹⁸.

No blocking antibody to the classical mannose receptor has been described, so we were unable to carry out similar experiments to the above. However, we were able to compare uptake of MPC-32 in the presence and absence of this mannose receptor, using DC derived from mannose receptor deficient mice (Fig 3c). As shown in Figs 3d and 3e, uptake of MPC-32 was substantially lower in the absence of this receptor, particularly at lower concentrations, suggesting that this receptor has an important, but not exclusive role in MPC-32 uptake.

Distribution of MPC6 and linker stability within DC

Flow cytometry cannot readily distinguish between binding at the cell surface, and uptake into the cell. The distribution of MPC6 within dendritic cells was therefore followed by confocal microscopy. Both MPC6-32 and MPC-40 are seen clearly within the majority of DC. The MPC6 derivatives are concentrated into vesicles of heterogeneous shape and size, often particularly densely packed in the perinuclear region, but fill a large proportion of the cytoplasmic volume in some cells (Fig 4a). No obvious distinction could be observed between distribution of MPC6-32 and MPC6-40 and for brevity the remaining panels each show only a representative image using one inhibitor.

In light of the size and extent of MPC6-containing vesicles observed by confocal microscopy, we also examined the ultrastructure of DC which had taken up unlabeled MPC6 by transmission electron microscopy (Fig 4b). A number of DC from this group were indeed found to be packed with large electron dense vesicular structures, which sometimes filled a large proportion of the cytoplasm. The vesicles often contained a core dense of dense material, surrounded by less dense material. We hypothesise that within these structures MPC6 may form insoluble aggregates as it concentrates within endosomes, which may explain the extremely slow efflux observed in Fig 2a.

Since previous studies had demonstrated inhibition of OVA processing by MPC6, the extent of colocalisation of OVA and MPC6 was examined (Fig 4c). OVA was taken up very efficiently by DC and its distribution showed extensive colocalisation with that of the MPC6 derivatives. Thus MPC6 successfully targets those endocytic compartments which also contain exogenous protein antigens taken up by DC.

The nature of the compartments was examined in more detail by immunofluorescent microscopy. MPC6 distribution overlapped significantly with LAMP1, a marker of late endosomes/lysosomes. However, a significant proportion of LAMP1 positive vesicles did

not contain MPC6, confirming that lysosomes and endosomes are distinct compartments, and that MPC6 has only partial access to the lysosomal system. As expected, MPC6 showed little overlap with the Golgi apparatus (Fig 4d). The two targets of MPC inhibition within DC are the two aspartic proteinases cathepsin D and E. Cathepsin D is predominantly a lysosomal enzyme, and its distribution is similar to that of LAMP1. In contrast, cathepsin E is predominantly extralysosomal¹⁹. As described previously^{6,20}, its distribution is much more diffuse and reticular, and in contrast to the predominantly perinuclear distribution of cathepsin D, cathepsin E is also found at the cell periphery. MPC6 distribution showed significant overlap with both cathepsin D and E (yellow areas in Figs 4f and g). However, some enzyme containing structures did not show any MPC6 fluorescence. Interestingly, small cathepsin E containing vesicles were sometimes seen closely juxtaposed to, but distinct from the much larger endocytic vesicles containing MPC6 (Fig 4g, detail).

The design of MPC6 incorporates a disulfide bond containing linker. The rationale for this design is based on a considerable body of literature suggesting that the intracellular environment favours reductive cleavage of such disulfide-containing linkers^{8,21}. We therefore hypothesised that cleavage of the disulfide linker of MPC6 would liberate pepstatin from the carrier and thus improve its bioavailability profile within the cell. However, the experiments shown in Figs 1-3 did not reveal much difference between the functional properties of MPC6-32, in which the fluorophore is attached to the BSA side of the linker, and MPC-40, in which it is attached to the pepstatin side of the linker. Furthermore, a recent paper has questioned the hypothesis of a reductive endosomal environment²².

We therefore tested the hypothesis directly, by synthesising two analogues of MPC6-32, in which the TMR fluorescence is quenched by a QSY-9 group added to the other side of a linker. MPC6-98 **9** (Fig 5a), containing a disulfide bonded linker equivalent to that in MPC6 between the TMR and QSY-9 groups, was again synthesised from **3** via selective deprotection, derivatisation with QSY-9 and removal of the Fmoc group to give **10**. This was followed by formation of the iodoacetamide and conjugation to neomannosylated BSA to give **9** (Figure 5a). As a control, the analogue MPC6-105 **11** (Fig 5a), containing a simple aliphatic linker, resistant to reductive cleavage, was synthesised from 1,3-diaminopropane via a similar route (Supplementary Information). For ease of synthesis, the pepstatin moiety was omitted from both quenched compounds.

Preliminary experiments demonstrated that the TMR-dependent fluorescence of MPC6-98 increased 10-20 fold on reduction with dithiothreitol, while in contrast MPC6-105 was unaffected, confirming that the quenching was effective, and could be reversed by cleavage of the disulfide bond. The uptake and fluorescence of both compounds by DC was then compared to that of MPC6-32, using flow cytometry (Fig 5b). Unexpectedly, we could find no evidence of cleavage of MPC6-98 even after a six hour incubation with DC, and indeed there was no significant difference in emission between MPC6-98 and MPC6-105. In order to reconcile the lack of linker cleavage with the observed potency of MPC6 in antigen processing and enzymatic functional assays, one must hypothesise that the pepstatin in MPC6 retains activity even when bound to linker and carrier. This hypothesis was tested by measuring the relative potency of MPC6 and pepstatin in cell free assays of cathepsin D and

E inhibition. As shown in Fig 5c, MPC6 was only about 2-3 fold less potent compared to free pepstatin, a decrease which may be accounted for by the incomplete coupling of pepstatin/linker to the BSA carrier as discussed above. Despite the attachment of a large carrier moiety, therefore, the pepstatin within MPC6 retains almost all its potency as a proteinase inhibitor.

Functional inhibition of aspartic proteinase activity by MPC6

Confocal microscopy demonstrated targeting of MPC6 to cathepsin D/E containing intracellular compartments. However, this approach cannot give quantitative information on the efficiency of enzymatic inhibition, particularly as the antibodies to the cathepsins do not distinguish between mature (active) enzyme, and immature (inactive) precursor. Functional inhibition of aspartic proteinase activity by MPC6 was therefore assessed using two approaches. In the first, DC were allowed to take up MPC6 for differing times, and then lysed, and proteinase activity in the lysate at pH 4 was measured using a quenched fluorescein substrate which is efficiently cleaved by both cathepsin D and E ²³ (Fig 6a). In agreement with the uptake data shown in Fig 1, inhibition is both time and dose dependent. Levels of inhibition reached 60-70% at 10 μ M MPC6 (the maximum tested), after exposure to MPC6 over 3-6 hours. Addition of pepstatin after cell lysis inhibits over 95% proteinase activity (Fig 5b), confirming that the assay is indeed selective for aspartic proteinase activity. Consistent with the very slow efflux of inhibitor observed, inhibition is long lasting, since cells which are allowed to take up MPC6 for three hours, washed and then incubated in the absence of inhibitor remain efficiently inhibited even after 18 hours (Fig 6c).

Activity of aspartic proteinases in DC was also measured using a flow cytometric assay, using the active site specific probe BODIPY-FL pepstatin (Fig 6d). In this assay, DC are fixed and permeabilised at acidic pH, and then incubated in the presence of BODIPY-FL pepstatin, in the presence or absence of excess pepstatin ²⁴. Incubation of DC with MPC6 (10 μ M) for three hours resulted in 60-80% inhibition of specific binding of the active site probe. Furthermore, MPC6 inhibited BODIPY-FL pepstatin binding equally both in DC from mice lacking cathepsin D and in DC from mice lacking cathepsin E. Thus MPC6 is able to target both cathepsin D and cathepsin E containing compartments in these DC.

The activity of MPC6 in inhibiting antigen processing of protein antigens is explored in fig 7. Initial dose response curves demonstrated that MPC6 maximally inhibited processing of OVA presentation to the specific T cell hybridoma DO11.10, but did not block antigen presentation of the synthetic peptide coding the OVA sequence 323-339, at concentrations of 10 μ M (Fig 7a). This concentration was used in all subsequent experiments. In order to try and quantify the efficiency of blocking, DC were incubated with a fixed concentration of OVA and MPC6, and then fixed with glutaraldehyde to block further processing. Different numbers of DC were then cocultured with DO11.10 cells (Fig 7b). A comparison of dose responses in the presence or absence of inhibitor suggested that MPC6 increases the number of cells required to give an equivalent response by around one order of magnitude, consistent with a 90% decrease in number of OVA peptide/MHC complexes formed in the presence of the inhibitor. A similar dose response was observed using DC isolated directly from mouse spleen (Fig 7c), rather than differentiated from bone marrow in vitro. DO11.10

is a rather insensitive T cell line, requiring 1-2mg/ml OVA for efficient stimulation. We therefore tested MPC6 using OTII cells, TcR transgenic T cells recognising the same peptide sequence of OVA, but requiring 2-3 orders of magnitude less antigen (and presented by a different MHC class II haplotype). MPC6 showed similar levels of inhibition of processing of OVA in this model (Fig 7d), confirming that the efficient inhibition observed was not specific either to the DO11.10 line used as indicator, or the particular strain of MHC or mouse. The sensitivity of antigen processing to MPC6 was different for different epitopes. Thus no inhibition of processing was observed when using MF2 (Fig 7e) or 3DO18.3 (Supplementary Information Fig 4), two T cell lines which recognise a different portion of the OVA sequence. In contrast, MPC6 did inhibit processing of MSP1 –19, a fragment of a protein from *Plasmodium chabaudi chabaudi*^{25,26} (Fig 7f). Inhibition was not therefore a special feature of the single OVA epitope 323-339.

The exogenous class II MHC antigen processing pathway requires two proteolytic events, the cleavage of antigen into MHC-binding peptides, and the cleavage of invariant chain, a protein which is associated with MHC in the ER, and prevents binding until it is proteolytically degraded and removed. The proteinases responsible for Ii degradation remain poorly characterised²⁷, although early studies implicated aspartic proteinases^{28,29}. It remained possible, therefore, that the effect of MPC6 could be attributed to its effect on invariant chain cleavage, rather than a direct effect on antigen proteolysis. In order to assess this possibility directly, DC were loaded with MPC6, and invariant chain degradation followed by pulse-chase metabolic labelling, and immunoprecipitation (Fig 7g). At the concentrations which led to profound inhibition of antigen processing, MPC6 failed to block or retard invariant chain degradation.

In vivo targeting of DC by MPC6

The selectivity of MPC6 was next examined in vivo, by injection of MPC6-40 intravenously into mice. Mice were sacrificed after three hours, and spleen cells isolated and analysed by flow cytometry (Fig 8a). An initial analysis of uptake on unfractionated spleen cells, shows that MPC6-40 was taken up by splenic CD11c positive DC (10-20% positive), but much less efficiently by lymphocytes (<5% positive). In order to analyse the specificity in more detail, CD11c cells were enriched by magnetic bead separation and the CD11b+ (myeloid) and CD11b- (lymphoid) cells³⁰ were analysed separately (Fig 8b). MPC6-40 was found selectively in the myeloid (CD11b+) DC population, and was inefficiently taken up by the CD11b DC. In agreement with this observation, MPC-40 could be detected in the CD11c +CD8- population (the equivalent of CD11b+), but not in the CD11c+CD8- population (Supplementary Information Fig 5). Significant staining was still observed 18 hours after injection, although the levels were reduced compared to the three hour time point.

The large molecular weight of MPC6 should limit access to non-lymphoid tissue via the endothelial blood vessel wall, but access of the inhibitor may occur at sites of inflammation when the barrier becomes more leaky. In order to test this hypothesis, mice were injected with MPC6-40 intravenously, and peritoneal cells were collected either in unstimulated mice (Fig 8c) or after inducing peritoneal inflammation by prior injection of thyoglycollate³¹. The peritoneum contained lymphocytes, granulocytes, CD11b+CD11c- macrophages, and

CD11b+CD11c+ DC. MPC6-40 could not be detected in any population in unstimulated mice, confirming that the inhibitor did not cross the endothelium efficiently (fig 8c). In contrast, significant staining was observed in both macrophages and DC after thyoglycollate (fig 8d).

Conclusion

This study describes the synthesis and functional properties of an inhibitor/carrier conjugate MPC6 which targets the aspartic proteinase inhibitor pepstatin to antigen presenting cells. A major goal of the study was to incorporate fluorescent groups into the basic structure which would allow efficient tracking of the conjugate by fluorescence microscopy or flow cytometry. The tetramethyl rhodamine (TMR) label chosen proved a good compromise between ease of chemical synthesis and good optical properties, allowing multiparameter analysis in combination with most of the commonly used fluorophores such as FITC, APC and the PE-Cy5/7 tandem dyes. This approach therefore allowed tracking of MPC6 inhibitor within several subpopulations of heterogeneous cell mixtures both in vitro and ex vivo. This is a particularly important consideration in following DC targeting, since these cells are usually only a small minority of lymphoid tissue in vivo, and consist of several subtypes with different function³⁰.

Using this fluorescent tracking approach, we demonstrated that MPC6 is avidly internalised by a variety of DC. Uptake was slow (compared, for example to the very rapid binding of antibody conjugates to their target), and required micromolar concentrations of inhibitor. Both these features, as well as the uptake block induced at 4°C and the competitive block in the presence of BSA mannose are compatible with a model of mannose-receptor facilitated uptake. DC express a number of receptors able to bind macromolecules containing mannose³². The reduced uptake of MPC6 in the absence of the classical mannose receptor clearly demonstrates an important role for this receptor on bone marrow derived DC in vitro, but other members of the lectin family may well contribute in vivo. Further studies will be required to more precisely identify the contribution of each receptor on different DC and macrophage subsets in vivo.

The classical mannose receptor has a relatively low ligand binding avidity. However, low affinity reversible binding to a mannose receptor effectively increases the local concentration at the cell surface, leading to enhanced uptake via endocytosis³³. The ability to continually accumulate inhibitor over an 18 hour period, the very slow efflux rates and the sensitivity of the uptake to chloroquine further suggests that MPC6 does not remain bound to the receptor, but dissociates at acidic endosomal pH, presumably allowing the receptor to recycle for further rounds of uptake. It remains unclear why MPC6 is not then lost from the cell, but a plausible hypothesis supported by the ultrastructural evidence of large number of very electron rich dense vesicles, is that the high concentrations achieved within the endo-lysosomal compartment lead to aggregation, thus trapping the inhibitor within the cell. These properties of MPC6 require relatively high extracellular concentrations, for prolonged periods of time. However, the low affinity and hence reversible binding of MPC6 allows a recycling mechanism to occur, which can achieve very high levels of intracellular inhibitor. In contrast, antibody conjugate delivery depends on

high affinity binding, which is fast and requires low concentrations of extracellular conjugate. However, the high affinity of the antibody/antigen interaction effectively means the interaction is irreversible, limiting uptake to the amount of antibody target present in the cell.

Confocal microscopy and enzymatic studies demonstrated that MPC6 is internalised to the antigen processing compartments of DC, which contain both internalised exogenous antigens, and the two aspartic proteinases cathepsin D and E ³⁴. Other compartments containing both proteinases clearly exist, presumably accounting for the fact that only partial inhibition of proteinase activity was achieved. The nature of this heterogeneity remains unclear, but both enzymes may be stored in storage vesicles (perhaps as proenzymes) and only released into the appropriate endosomal compartment upon appropriate stimulation. Such a regulated delivery model is compatible with the recent data ³⁵ suggesting that efficient antigen processing occurs only in the presence of appropriate microbial stimulation.

An unexpected finding of our study was the apparent lack of role for the disulfide bond within the linker which joins the albumin and pepstatin portions of the conjugate. Using quenched fluorescent substrates, we were unable to find any evidence for substantial breakage of the linker within DC, even over a six hour period. The inclusion of disulfide bond linkages in macromolecular drug delivery systems has become commonplace, and is based on the widely held belief that the endosomal/lysosomal system provides a highly reductive environment, leading to cleavage of such linkers and release of active drug. The discovery of several specific enzymatic pathways for facilitating this S-S bond breakage ⁸ provided further apparent support for this model. However, relatively few studies have directly measured reductive cleavage of such linkers in situ. One recent study which did set out to measure cleavage also found no evidence for reduction within the endosomal system ²², whereas a second recent study demonstrated disulfide bond cleavage within endosomes ²¹. The reasons for these discrepancies remain unclear, although they may be related to the different cell types and receptor targeting used in the two reported studies. However, one important consideration in the present study is that the disulfide bond within the MPC6 linker does not have the same structure as the Cys-S-S-Cys bond found in natural protein disulfides, and may therefore not act as an efficient substrate for the oxidoreductase enzymes such as GIILT which have been described within DC ³⁶. Our work has also demonstrated that for MPC6 to function effectively as a targeted inhibitor of cathepsins D and E, dissociation of inhibitor and carrier may not be essential. This was also demonstrated in a recent study of targeting of cysteine proteases by mannose cluster-inhibitor conjugates in APCs ³⁷. Further work on linker characterisation may improve the susceptibility of conjugates to cellular reduction, and hence improve the efficiency of delivery.

Despite the partial inhibition of proteinase activity, and the lack of linker cleavage, MPC6 was remarkably efficient at blocking processing of OVA by DC. Comparison of DC dose response curves suggested that MPC6 reduced the number of loaded MHC peptide complexes by as much as 90% . Thus MPC6 appears to effectively target the pool of aspartic proteinase which is specifically required for antigen processing to occur. These studies support and extend our earlier studies proposing a non-redundant role for cathepsin E in the processing of OVA ⁶, although the relative importance of cathepsin D and E has not been

further explored in the current study. The sensitivity of several other T cell epitopes to MPC6 inhibition was also explored. It is interesting that the two MPC6 sensitive epitopes OVA 323-339, and MSP1 1690-1709 are both within compact and proteolytically resistant domains of globular proteins³⁸. In contrast, the two MPC6 resistant epitopes, MF2 and 3DO18.3 T cells recognise epitopes which are exposed on the OVA protein surface. One may speculate that aspartic proteinase degradation may therefore be a specific requirement for releasing peptides from particularly resistant protein domains, although further work is required to test this hypothesis.

Finally, an important aspect of targeted delivery is the behaviour of conjugates in vivo. This is especially important in the case of large molecular weight conjugates such as MPC6, since these molecules are unlikely to efficiently cross the endothelial barrier, and therefore penetrate many tissues. MPC injected intravenously did indeed target spleen DC, consistent with the open blood supply to this organ. Uptake was selective, since very little MPC6-40 could be detected in lymphocytes, or CD11b-CD8+ CD11c+ lymphoid DC, while fluorescence could readily be detected in CD11b+,CD8-,CD11c DC, which are the population principally involved in processing/presentation of exogenous antigens via Class II MHC to CD4+ T cells. The large size of MPC6, however, together with its tropism for antigen presenting cells, may paradoxically offer some benefits. Its size will prevent its access to most tissues thus reducing any possible toxicities, but it will gain preferential access to immunologically active and/or inflammatory sites in which antigen presenting cells are typically most active, since these tissues typically show high endothelial permeability and accessibility. This hypothetical selective in vivo localisation was confirmed using the classical inflammatory peritoneal model.

In conclusion, we have described a versatile modular approach to the synthesis of macromolecular carriers targeting inhibitors to the antigen presenting cell compartment of the immune system. The strategy has allowed us to incorporate diverse functional properties, including increased solubility in biological solutions, fluorescence at wave lengths suitable for tracking via confocal microscopy or flow cytometry, targeting via specific pattern recognition receptors, and delivery and accumulation within the endosomal intracellular compartment. These properties were achieved with little effect on the potency of the core inhibitor moiety pepstatin, and good inhibitory activity against the target antigen processing pathway. Targeted delivery via PRRs may therefore provide significant advantages for delivering high concentrations of immunomodulators to DC. Further modification of each element of the modular design will allow enhanced targeting selectivity, improved intracellular delivery, and delivery of a range of immunomodulators. Such targeted inhibitors will provide valuable tools for dissection of the immune system, as well as for delivering immunomodulators for prophylaxis or therapy.

METHODS

Details of animals, culture media and cell isolations are all given in Supporting Information.

In vitro uptake experiments

DC ($0.5\text{--}2 \times 10^5/\text{well}$) were cultured in the presence of MPC6-32, MPC6-40, MPC6-98 or MPC6-105 at 37°C , 5% CO_2 for various times (15 minutes – 18 hours) in a total volume of 200 μl complete medium. The cells were washed twice in HBSS by centrifugation and then fixed in 3.8% formaldehyde. Fluorescence was analysed on a FACSArray Bioanalyser (BD Biosciences). TMR fluorescence intensity was measured in the yellow channel. In some experiments, cells were processed for immunofluorescence prior to fixation. The cells were put on ice, and non-specific binding blocked by addition of 10 μl rabbit serum for 10 minutes. Conjugated antibody (CD11c-PE (clone N418), CD11c-APC (clone N418), CD11c-PE-Cy7 (clone N418) or appropriate isotype controls, all purchased from BD Biosciences) diluted according to manufacturer's recommendations was added to each well and left for 45 minutes at 4°C . The cells were washed twice in cold HBSS, fixed and analysed as above.

Mannose receptor studies

The anti-DEC205 antibody NLDC145 was purified from culture hybridoma supernatant by ammonium sulphate precipitation and DEAE-sephadex ion exchange using standard methods. The hybridoma was obtained from Prof. Reis e Sousa, Cancer Research UK. Mannose receptor was visualised using a biotinylated anti-CD206 antibody (Cambridge Biosciences, # 123003) and streptavidin-APC. The mannose receptor deficient mice have been described previously ³⁹.

Confocal microscopy

Dendritic cells were incubated in the presence of MPC6-32 or MPC6-40 (1 μM) for three hours in CM. In some experiments, ovalbumin-FITC was added (1 mg/ml) for the last hour incubation. The cells were washed in HBSS and 5×10^4 cells were allowed to adhere for 30 minutes on poly L-lysine (Sigma Aldrich, 100 $\mu\text{g}/\text{ml}$ in water) coated 18 mm circular cover slips, at 4°C . The cells were fixed for 10 minutes in 4% paraformaldehyde and mounted in DAPI containing mounting medium (Vectashield). In some experiments, the DC were further processed for immunofluorescence prior to mounting. After fixation in paraformaldehyde, DC were permeabilised in cold methanol (-20°C) for three minutes (methanol rather than detergent permeabilisation was found to be necessary in order to preserve localisation of MPC6-32 and 40). The DC were washed in Tris-buffered saline (TBS), blocked in 20% goat or rabbit serum, and then stained with rabbit anti-LAMP1 (1:100 dilution in blocking buffer, Abcam # cat no ab24170), rabbit anti giantin (1:200 dilution in blocking buffer, Covance #PRB-114C), goat anti anti-cathepsin D or goat anti-cathepsin E (1:20 dilution in blocking buffer, R&D) for 2-3 hours. The coverslips were washed three times in TBS, and then incubated in rabbit anti-goat Ig FITC (DAKO) or goat anti-rabbit Ig FITC (DAKO) for 1 hour, washed and mounted as above. The images were collected and analysed on a Leica confocal microscope, using Leica analysis software.

In vivo uptake experiments

Mice (with or without previous thioglycollate injection) were injected intravenously with 200 μ l MPC6-40 (5 mg/ml) solution. Mice were sacrificed and spleens and/or peritoneal exudate cells were harvested after 3 hours or 18 hours.

T cell presentation

Activation of the T cell hybridomas DO11.10 (OVA 323-339, I-A^d), MF2 (257 – 278, I-A^b) (kind gift of Dr. K. Rock, University of Massachusetts), and B7 (*Plasmodium chabaudi* MSP1 1690-1709) was measured by assaying IL2 release as described previously²⁵. The MSP1 1-19 protein was prepared as described previously²⁶. Activation of T cells from the OTII TcR transgenic mouse (OVA 323-339, I-A^b) was measured by assaying for 3H thymidine incorporation as described previously⁴⁰.

Antigen processing assay

DC were precultured in the presence of MPC6 for 30 minutes – 3 hours (as detailed in Legends) before addition of appropriate antigen and T cell (see above) for 18-24 hours. In some experiments, antigen and inhibitor were removed by washing after a further two hour incubation and further antigen processing was blocked by fixation in 0.5% glutaraldehyde solution in phosphate buffered saline (PBS) (Sigma-Aldrich), for 30 seconds. Excess glutaraldehyde was quenched by adding an equal volume of complete medium, and the cells were washed twice. DC and T cell were then cocultured for a further 18-24 hours as above.

Invariant chain immunoprecipitation

Details in Supporting Information.

Proteolysis assays

1. Enzymatic—Purified recombinant human cathepsin D (R&D) or E (R&D), or DC lysate was incubated in the presence of the specific aspartic proteinase quenched fluorogenic peptide substrate Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-DArg-NH₂²³ (200 μ M, M-2455, Bachem) and buffer (1 M acetate, pH 4.0) for 10 minutes at 37°C. Typically the incubation mixture contained 5 μ l substrate (final concentration 10 μ M), and 10 μ l of enzyme or lysate, 5-10 μ l inhibitor, and a total volume of 100 μ l. The reaction was stopped by addition of 1 ml cold trichloroacetic acid (5% w/v). Fluorescence was measured in a fluorimeter (Perkin Elmer LS50B) set at excitation 328; emission 393. For measurement of enzymatic activity in DC (2×10^5) after incubation in the presence of MPC6, cells were washed three times to remove all exogenous inhibitor, and then lysed in 200 μ l 0.1% Triton-X in 0.15 M sodium acetate buffer, pH 4.5. The cell lysate was incubated for 15 minutes on ice, mixed, and then diluted further (1:10-1:50) in 0.15 M sodium acetate buffer, pH 4.5 without detergent. An aliquot of the diluted lysate was assayed as above.

2. Flow cytometric—DC (2×10^5) were incubated for three hours in the presence of MPC6 (10 μ M). The cells were washed, and fixed in 4% paraformaldehyde in 0.15 M sodium acetate buffer, pH 4.5. The cells were permeabilised by adding an equal volume of Triton-X100 (0.2%, in 0.15 M sodium acetate buffer, pH 4.5), and then incubated with

BODIPY-FL pepstatin²⁴ (500 nM final, InVitrogen) with and without excess pepstatin (100 μ M) for 30 minutes, room temperature. The cells were washed twice with 0.15 M sodium acetate buffer, pH 4.5. Fluorescence intensity was measured by flow cytometry on a FACSCalibur (BD Biosciences). Specific aspartic protein dependent fluorescence is given by the difference in intensity between samples with and without excess unlabelled pepstatin. The fluorescence intensity was stable for at least 24 hours.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The study was supported by the BBSRC (BB/D005469/1) under the SCIBS initiative. ES was supported by a MRC studentship. We are grateful to Prof. Norbert Koch (University of Bonn) for the gift of antibodies for the invariant chain precipitation.

Reference List

1. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. *Annu. Rev. Immunol.* 2005; 23:975. [PubMed: 15771591]
2. Shortman K, Lahoud MH, Caminschi I. Improving vaccines by targeting antigens to dendritic cells. *Exp. Mol. Med.* 2009; 41(2):61. [PubMed: 19287186]
3. Frison N, et al. Oligolysine-based oligosaccharide clusters: selective recognition and endocytosis by the mannose receptor and dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin. *J. Biol. Chem.* 2003; 278(26):23922. [PubMed: 12695508]
4. Bedouet L, et al. Uptake of dimannoside clusters and oligomannosides by human dendritic cells. *Biosci. Rep.* 2001; 21(6):839. [PubMed: 12166831]
5. Free P, et al. Mannose-pepstatin conjugates as targeted inhibitors of antigen processing. *Org. Biomol. Chem.* 2006; 4(9):1817. [PubMed: 16633575]
6. Chain BM, et al. The expression and function of cathepsin E in dendritic cells. *J. Immunol.* 2005; 174(4):1791. [PubMed: 15699105]
7. Steinfeld R, et al. Cathepsin D deficiency is associated with a human neurodegenerative disorder. *Am. J. Hum. Genet.* 2006; 78(6):988. [PubMed: 16685649]
8. Saito G, Swanson JA, Lee KD. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. *Adv. Drug Deliv. Rev.* 2003; 55(2):199. [PubMed: 12564977]
9. Peters, T. All about Albumin. Biochemistry, Genetics and Medical Applications. Academic Press; New York: 1996.
10. Wilson, Janet M., et al. A spectrophotometric method for studying the rates of reaction of disulfides with protein thiol groups applied to bovine serum albumin. *J. Am. Chem. Soc.* 1980; 102(1):359.
11. Riener CK, Kada G, Gruber HJ. Quick measurement of protein sulfhydryls with Ellman's reagent and with 4,4'-dithiodipyridine. *Anal. Bioanal. Chem.* 2002; 373(4-5):266. [PubMed: 12110978]
12. Naik SH, et al. Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. *J. Immunol.* 2005; 174(11):6592. [PubMed: 15905497]
13. Sixt M, et al. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. *Immunity.* 2005; 22(1):19. [PubMed: 15664156]

14. Benito JM, et al. Optimizing saccharide-directed molecular delivery to biological receptors: design, synthesis, and biological evaluation of glycodendrimer-cyclodextrin conjugates. *J. Am. Chem. Soc.* 2004; 126(33):10355. [PubMed: 15315450]
15. Bonifaz L, et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. *J. Exp. Med.* 2002; 196(12):1627. [PubMed: 12486105]
16. McKenzie EJ, et al. Mannose receptor expression and function define a new population of murine dendritic cells. *J. Immunol.* 2007; 178(8):4975. [PubMed: 17404279]
17. Small M, Kraal G. In vitro evidence for participation of DEC-205 expressed by thymic cortical epithelial cells in clearance of apoptotic thymocytes. *Int. Immunol.* 2003; 15(2):197. [PubMed: 12578849]
18. East L, Isacke CM. The mannose receptor family. *Biochim. Biophys. Acta.* 2002; 1572(2-3):364. [PubMed: 12223280]
19. Zaidi N, Kalbacher H. Cathepsin E: a mini review. *Biochem. Biophys. Res. Commun.* 2008; 367(3):517. [PubMed: 18178150]
20. Sealy L, et al. Regulation of cathepsin E expression during human B cell differentiation in vitro. *Eur. J. Immunol.* 1996; 26(8):1838. [PubMed: 8765029]
21. Yang J, et al. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. *Proc. Natl. Acad. Sci. U. S. A.* 2006; 103(37):13872. [PubMed: 16950881]
22. Austin CD, et al. Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. *Proc. Natl. Acad. Sci. U. S. A.* 2005; 102(50):17987. [PubMed: 16322102]
23. Yasuda Y, et al. Characterization of new fluorogenic substrates for the rapid and sensitive assay of cathepsin E and cathepsin D. *J. Biochem.* 1999; 125(6):1137. [PubMed: 10348917]
24. Chen CS, et al. Probing the cathepsin D using a BODIPY FL-pepstatin A: applications in fluorescence polarization and microscopy. *J. Biochem. Biophys. Methods.* 2000; 42(3):137. [PubMed: 10737220]
25. Quin SJ, et al. Low CD4(+) T cell responses to the C-terminal region of the malaria merozoite surface protein-1 may be attributed to processing within distinct MHC class II pathways. *Eur. J. Immunol.* 2001; 31(1):72. [PubMed: 11169440]
26. Hensmann M, et al. Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response. *Eur. J. Immunol.* 2004; 34(3):639. [PubMed: 14991593]
27. Maehr R, et al. Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice. *J. Immunol.* 2005; 174(11):7066. [PubMed: 15905550]
28. Mizuochi T, et al. Both cathepsin B and cathepsin D are necessary for processing of ovalbumin as well as for degradation of class II MHC invariant chain. *Immunol. Lett.* 1994; 43(3):189. [PubMed: 7721331]
29. Kageyama T, et al. Potential sites for processing of the human invariant chain by cathepsins D and E. *Biochem. Biophys. Res. Commun.* 1996; 223(3):549. [PubMed: 8687433]
30. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. *Nat. Rev. Immunol.* 2002; 2(3):151. [PubMed: 11913066]
31. Griffin FM Jr. et al. Studies on the mechanism of phagocytosis. I. Requirements for circumferential attachment of particle-bound ligands to specific receptors on the macrophage plasma membrane. *J. Exp. Med.* 1975; 142(5):1263. [PubMed: 1194852]
32. van Kooyk Y. C-type lectins on dendritic cells: key modulators for the induction of immune responses. *Biochem. Soc. Trans.* 2008; 36(Pt 6):1478. [PubMed: 19021579]
33. Levine TP, Chain BM. Endocytosis by antigen presenting cells: dendritic cells are as endocytically active as other antigen presenting cells. *Proc. Natl. Acad. Sci. U. S. A.* 1992; 89:8342. [PubMed: 1355605]
34. Medd PG, Chain BM. Protein degradation in MHC class II antigen presentation: opportunities for immunomodulation. *Semin. Cell Dev. Biol.* 2000; 11(3):203. [PubMed: 10906277]

35. Blander JM, Medzhitov R. Regulation of phagosome maturation by signals from toll-like receptors. *Science*. 2004; 304(5673):1014–1018. [PubMed: 15143282]
36. Maric M, et al. Defective antigen processing in GILT-free mice. *Science*. 2001; 294(5545):1361. [PubMed: 11701933]
37. Hillaert U, et al. Receptor-mediated targeting of cathepsins in professional antigen presenting cells. *Angew. Chem. Int. Ed Engl*. 2009; 48(9):1629. [PubMed: 19156780]
38. Babon JJ, et al. Structural studies on *Plasmodium vivax* merozoite surface protein-1. *Mol. Biochem. Parasitol*. 2007; 153(1):31. [PubMed: 17343930]
39. Lee SJ, et al. Mannose receptor-mediated regulation of serum glycoprotein homeostasis. *Science*. 2002; 295(5561):1898. [PubMed: 11884756]
40. Tulone C, et al. Natural cathepsin E deficiency in the immune system of C57BL/6J mice. *Immunogenetics*. 2007; 59(12):927. [PubMed: 18000662]

a)

b)

Fig 1.

a) Structures of pepstatin **1** and MPC6 **2**. b) Scheme showing synthetic route to MPC6-32 **7** and MPC6-40 **10**. TMR, tetramethylrhodamine; Fmoc, 9-fluorenylmethyloxycarbonyl; Boc, *tert*-butoyloxycarbonyl; TFA, trifluoroacetic acid.

Fig 2. Uptake of MPC6 by DC in vitro

a) Uptake of MPC6-32 by GM-CSF bone marrow derived DC in vitro. GM-CSF DC (2×10^5) were cultured for three hours at 37°C with MPC6-40 (0.1 μM), washed and immunolabelled with antibodies against CD11c. The cells were fixed and analysed by flow cytometry. b) GM-CSF bone marrow derived DC were incubated for different times, and with different concentrations of MPC6-32 (left panel) or MPC6-40 (right panel), and uptake analysed by flow cytometry. The graph shows median fluorescent intensity (MFI) in the TMR channel. c) As for b, showing staining after 6 hour and 18 hour (overnight) incubation

at two concentrations of MPC6. d) Uptake of MPC6-32 by Flt3L bone marrow derived DC in vitro. DC (5×10^4) were cultured for three hours at 37°C with MPC6-32 (0.1 μ M), washed and stained for CD11b and CD11c expression. The cells were fixed and analysed by flow cytometry. The left panel shows the two CD11c DC populations. The right panels show TMR staining in cells incubated with (solid line) or without (dotted line) MPC6-32. e) Efflux of MPC6-32 from DC. GM-CSF bone marrow derived DC (5×10^4) were cultured for 2 or 18 hours at 37°C with MPC6-32 (0.5 μ M), and then cultured for varying times in the absence of exogenous MPC6-32, before fixation. Uptake was analysed by flow cytometry. The graph shows median fluorescent intensity (MFI) in the TMR channel. f) Flt3L bone marrow derived DC were incubated for different times, and with different concentrations with MPC6-32 at 37°C (left panel) or 40°C (right panel), and uptake analysed by flow cytometry. The graph shows median fluorescent intensity (MFI) in the TMR channel. g) GM-CSF bone marrow derived DC were incubated for 6 hours with different concentrations of MPC6-32, in the presence (dotted line) or absence (solid line) of chloroquine (100 μ M) and uptake analysed by flow cytometry. The graph shows median fluorescent intensity (MFI) in the TMR channel.

Fig 3. Uptake of MPC6 is mediated by mannose receptors

a) Competitive inhibition of MPC6 uptake. GM-CSF bone marrow derived DC (5×10^4) were cultured for three hours at 37°C in the presence of different concentrations of mannose-BSA or BSA. Uptake was analysed by flow cytometry. The graph shows median fluorescent intensity (MFI) in the TMR channel. **b)** The uptake of MPC6 is not blocked by antibody to the DEC205 receptor. GM-CSF bone marrow derived DC (5×10^4) were cultured for 30 minutes in the presence or absence of different amounts of purified anti-DEC205 antibody (or as control an isotype matched anti-class II MHC antibody). MPC6-32 (at high and low concentrations as shown) was then added for a further three hours at 37°C. Uptake was analysed by flow cytometry. The graph shows median fluorescent intensity (MFI) in the TMR channel. **c)** Mannose receptor expression is detectable on wild type but not mannose receptor deficient mouse bone marrow derived DC. Mannose receptor expression was detected by flow cytometry using a biotinylated anti-mannose receptor antibody, and APC-streptavidin. **d)** The uptake of MPC6-32 is lower in the absence of mannose receptor. Bone marrow derived DC from wild type and mannose receptor deficient mice were incubated in different concentrations of MPC6 for 3 hours at 37°C. Uptake was analysed by flow cytometry. The graph shows median fluorescent intensity (MFI) in the TMR channel. **e)** A representative fluorescent histogram of the data in d), using a concentration of 0.13 μ M MPC-32.

Fig 4. Intracellular localisation of MPC6

a) GM-CSF bone marrow DC were incubated for three hours in the presence of MPC6-32 (1 μ M) and MPC6-40 (1 μ M), washed, fixed and processed for confocal microscopy. The panels show low (scale bar = 40 microns) and high (scale bar = 4 microns) magnifications showing the presence of intracellular labelled MPC6 in discrete vesicular structures. b) GM-CSF bone marrow DC were incubated for three hours in the presence of MPC6-32 ((1 μ M), washed, fixed and processed for transmission electron microscopy. c) As for a) but OVA labelled with fluorescein isothiocyanate (FITC) (1 mg/ml) was added to the cultures one

hour prior to the end of the incubation period. Note the close overlay between OVA and MPC6 staining (scale bar = 4 microns). d), e), f) and g) As for a), but cells were stained after fixation and permeabilisation using antibodies for the lysosomal protein LAMP 1 (d), the Golgi marker giantin (e), and the proteinases cathepsin D (f) and E (g) (scale bar = 4 microns).

Fig 5. The role of disulfide bond cleavage in MPC6 activity

a) Scheme showing synthetic route to the quenched MPC6 analogue MPC6-98 (containing a disulfide bond in the linker between the quencher QSY-9 and the TMR) and the structure of MPC6-105 (without this disulfide bond). b) The uptake of MPC6-98, MPC6-105 and MPC6-32 (cf fig 2b) by GM-CSF bone marrow derived DC. The graph shows MFI of DC population after 6 hours incubation in presence of different compounds, plotted against compound concentration. c) The inhibition of cathepsin D and cathepsin E by MPC6 and pepstatin. Enzyme (1nM) was incubated in the presence of inhibitor at the concentration

shown, and proteinase tested using a quenched fluorescent peptide substrate as described in Methods. The graph shows the activity as a % of the activity in the absence of inhibitor.

Fig 6. Inhibition of aspartic proteinase activity in DC incubated with MPC6

a) GM-CSF DC were incubated in the presence of different concentrations of MPC6 for three hours. Excess MPC6 was removed by washing, the cells were lysed, and acid proteinase activity in 100 cell equivalents measured as described in Methods. Results are expressed as percentage inhibition relative to activity of cells without inhibitor. b) GM-CSF DC were incubated in the presence of MPC6 (10 μ M) for varying lengths of time. Cells were then washed and proteinase activity measured as in a). P – pepstatin (100 nM) was added after lysis. c) GM-CSF DC were incubated in the presence or absence of MPC6 (10 μ M) for three hours. Excess MPC6 was removed by extensive washing, and a proportion of cells were removed and proteinase activity measured as above (inhibition shown in column labelled 3). The remaining cells were incubated overnight in the absence of inhibitor, and

proteinase activity measured after a further eighteen hours culture (column marked 3 + 18). d) GM-CSF DC from cathepsin D deficient (CTSD $-/-$), cathepsin E deficient (CTSE $-/-$) or wild type litter mate controls (CTSD $+/+$ and CTSE $+/+$) were incubated in the presence (solid line) or absence (dashed line) of MPC6 (10 μ M) for three hours, and aspartic proteinase activity measured by staining with BODIPY-FL pepstatin as described in Methods. The filled histograms show fluorescent signal in the presence of excess unlabelled pepstatin (100 μ M). The bar chart below the FACS profiles show median fluorescent intensity (MFI) for each experimental group, after subtracting MFI in the presence of excess unlabelled pepstatin (100 μ M).

Fig 7. Inhibition of antigen processing in DC incubated with MPC6

a) GM-CSF DC (5000 cells) cultured from bone marrow of Balb/c mice were incubated with varying concentrations of MPC6, and cocultured with ovalbumin (OVA, 1 mg/ml) or OVA peptide (323-339, 1 $\mu\text{g/ml}$), and the T cell hybridoma DO11.10 (2×10^4 cells). IL2 release was measured after 24 hours. b) GM-CSF DC cultured from bone marrow of Balb/c mice were incubated with MPC6 (10 μM) for one hour, and then OVA (2 mg/ml) for a further two hours. Excess OVA and inhibitor was removed by washing, and the cells were fixed with glutaraldehyde as described in M and M. Different numbers of fixed DC were then

cocultured with DO11.10 cells (2×10^4), and IL2 release was measured after 24 hours. c) Splenic CD11c+ from Balb/c mice DC (105) were incubated with (squares) or without (diamonds) MPC6 (10 μ M) for three hours, and then cocultured with OVA for a further three hours. The DC were washed, and cocultured with DO11-10 cells as above. IL2 release was measured after 24 hours. d) GM-CSF DC cultured from bone marrow of C57Bl mice were incubated with (squares) or without (diamonds) MPC6 (10 μ M) for three hours, and then cocultured with OVA (left panel) or OVA peptide 323-339 (right panel) for a further three hours. The DC were washed, and cocultured with OT-II transgenic T cells for 18 hours. Proliferation was measured by thymidine incorporation. e) GM-CSF DC cultured from bone marrow of C57Bl mice were incubated with (squares) or without (diamonds) MPC6 (10 μ M) for three hours, and then cocultured with OVA, and the T cell hybridoma MF2 (105 cells). IL2 release was measured after 24 hours. f) GM-CSF DC cultured from bone marrow of cathepsin D deficient or wild type litter mates were incubated with or without MPC6 (10 μ M), MSP1 protein or MSP1 peptide (marked as B7p), and the B7 T cell hybridoma. IL2 release was measured after 24 hours. g) GM-CSF bone marrow derived DC were pulsed labelled with S35 methionine in the presence or absence of MPC6 (10 μ M), and then cultured for the times shown in the absence of label. Cells were lysed and immunoprecipitated with anti-Ii antibody In-1, and the immunoprecipitate fractionated by PAGE. Control immunoprecipitates using rat Ig showed no bands at the molecular weights of Ii or class I MHC.

Fig 8. In vivo targeting of MPC6

a) Mice were injected intravenously with 1 mg MPC6-40 or left uninjected. Spleens were harvested after 3 hours, and cells stained for CD11c. The left panel shows the forward scatter/side scatter profile, and the two gated populations. The smaller populations consisted of >98% lymphocytes; the larger population contained >90% of the total CD11c+ DC population. The left panel shows the MPC6-40 signal (measured as TMR fluorescence) for the lymphocytes and the CD11c+ DC, for control (shaded) and MPC6-40 injected mice (three coloured histograms).

b) As for a), but the CD11c spleen cells were enriched by magnetic bead selection and then stained for CD11c and CD11b. The panels show the MPC6-40 signal (measured as TMR fluorescence) for the CD11b+ CD11c+ DC, and the CD11b-CD11c+ DC for control (shaded histogram) and MPC6-40 injected mice (empty histograms). One representative experiment of three.

c) Mice were injected intravenously with 1 mg MPC6-40 or left uninjected. Peritoneal exudates cells were harvested after 3 hours, and cells stained for CD11b and CD11c. The panels shows the MPC6-40 signal (measured as TMR fluorescence) for the CD11b+ CD11c-macrophages, and the CD11b+CD11c+ DC for control (shaded histogram) and MPC6-40 injected mice (empty histograms). One representative experiment of three.

d) As for c), but all mice received 2 ml thioglycollate (3%) three days prior to the MPC6-40 injection. One representative experiment of three.